These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17046236)

  • 1. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive biosimulation and virtual patients in pharmaceutical R and D.
    Bangs A
    Stud Health Technol Inform; 2005; 111():37-42. PubMed ID: 15718695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.
    Gieschke R; Reigner BG; Steimer JL
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of uncertainty about population parameters on pharmacodynamics-based prediction of clinical trial power.
    Kraiczi H; Frisén M
    Contemp Clin Trials; 2005 Apr; 26(2):118-30. PubMed ID: 15837435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological markers: utilization in drug development and approval].
    Gueyffier F; Dib M; Boissel JP
    Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimulation software is changing research.
    Ho RL; Bartsell LT
    Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in drug development.
    McCarthy AD; Kennedy JL; Middleton LT
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative risk modelling for new pharmaceutical compounds.
    Tang Z; Taylor MJ; Lisboa P; Dyas M
    Drug Discov Today; 2005 Nov; 10(22):1520-6. PubMed ID: 16257374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics and drug development: the path to safer and more effective drugs.
    Roses AD
    Nat Rev Genet; 2004 Sep; 5(9):645-56. PubMed ID: 15372086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecule based diagnosis].
    Akaza H; Ichikawa T; Tsuruo T; Shimada Y; Moriwaki H; Mori M; Noguchi S; Nakamura S; Saijo N; Sone S; Isonishi S; Ohashi Y; Hinotsu S; von Euler M; Blackedge G
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):125-33. PubMed ID: 14750337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How molecular profiling could revolutionize drug discovery.
    Stoughton RB; Friend SH
    Nat Rev Drug Discov; 2005 Apr; 4(4):345-50. PubMed ID: 15789121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures.
    Wright MC; Taekman JM; Barber L; Hobbs G; Newman MF; Stafford-Smith M
    Contemp Clin Trials; 2005 Dec; 26(6):646-59. PubMed ID: 16226924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.